{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-121607","form_type":"8-K","ticker":"SLDB","cik":"0001707502","company_name":"Solid Biosciences Inc.","filed_at":"2022-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.926999+00:00","generated_at":"2026-06-26T04:09:36.589154+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Solid Biosciences restructures, cuts 35% of staff; Q1 net loss $25.3M; COO resigns","bullets":["Headcount reduced ~35% to align resources behind SGT-001 and SGT-003; cash runway extended into Q2 2024.","COO Joel Schneider to resign effective May 27, 2022 to become CEO of a private gene therapy company.","Q1 net loss $25.3M vs $16.9M YoY; collaboration revenue $1.9M (down from $3.3M); R&D expense $19.9M.","Cash, equivalents and securities $180.1M as of March 31, 2022.","SGT-003 IND submission expected early 2023; SGT-001 transitioning to commercial-scale manufacturing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-121607","json":"https://secwatch.observer/filing/0001193125-22-121607.json","markdown":"https://secwatch.observer/filing/0001193125-22-121607.md","text":"https://secwatch.observer/filing/0001193125-22-121607.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1707502/000119312522121607/0001193125-22-121607-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1707502/000119312522121607/d326843d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T04:09:36.589154+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"204e9355e3","claim":"Joel Schneider resigned as Chief Operating Officer at Solid Biosciences Inc..","evidence_excerpt":"Joel Schneider, Chief Operating Officer of the Company, notified the Company of his intent to resign to accept a role as chief executive officer of a privately-held novel, viral-based gene therapy platform company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1707502/000119312522121607/0001193125-22-121607-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}